ArticleAntonie van Leeuwenhoek2026
Gas chromatography-mass spectrometry analysis of the secondary metabolites produced by Bacillus paramycoides BOK01 and Microbacterium barkeri BPATH02 and investigation of their antifungal activity against tea pathogens.
Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The present research investigates the chemical profile of secondary metabolites produced by Bacillus paramycoides BOK01 and Microbacterium barkeri BPATH02 rhizospheric bacteria originating from the tea rhizosphere and their antifungal activity against major tea pathogens. GC-MS analysis revealed that dimethyl sulphate (77.09%) was a major compound (Compound I) of B. paramycoides BOK01 and 1H-Purin-6-amine, [(2-fluorophenyl) methyl- (CAS) (Compound II; 16.88%), and docosane (Compound III; 11.75%) as putative major compounds in M. barkeri BPATH02. Furthermore, the ethyl acetate extract of both bacterial antagonists and compounds I, II, and III were evaluated for their efficacy against major tea pathogens, namely Exobasidium vexans, Pseudopestalotiopsis theae, and Fusarium concentricum causing respective blister blight, gray blight, and Fusarium dieback in tea crops using two-sealed-base-plate method. Laboratory screening of ethyl acetate (EA) extracts of both bacterial antagonists at 200 µg/mL provided a 65.95 to 82.5% range of growth inhibition of tested pathogens. At similar dose, compounds I, II, and III provided 70.88 to 77.53%, 67.7 to 78.0% and 71.8 to 73.07% range of growth inhibition of tested pathogens, respectively. Thus, this study shows that bacterial metabolites and their compounds are sources of putative antifungal agents, which can be harnessed for bio-fungicides development against tea diseases.
Indexed as
Identifiers
42667439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.